In plasma cell myeloma, the average serum IgG concentration was approximately six times higher than normal, regardless of whether Bence-Jones proteins were present or not. In five out of 88 cases the value for serum IgG was within the normal range; two of these patients had a solitary myeloma. The serum IgA and IgM averaged 22% of normal. The serum levels of the normal immunoglobulins in the patients with solitary myeloma were within the normal range or slightly decreased.
Two patients with extramedullary plasmacytoma showed a considerable increase in IgG (about 300%), normal IgA, and a moderate decrease in IgM, (about 40%).
In the potentially malignant type, the marked reduction of normal im munoglobulins (IgA, 21%; IgM, 24%) which reached the same degree as in plasma cell myeloma constituted more distinct characteristic than the increase in serum IgG (about 400%). The separation of the potentially malignant type from benign monoclonal gammopathy, proposed by the author, is based primarily on such an immunoglobulin pattern.9
In the malignant lymphoma group, the serum IgG levels exceeded the normal range in six of seven cases and the mean concentration was 228% of normal. Either the IgA or IgM levels were below the normal range in four of seven cases. In all cases of lymphosarcoma and reticulum cell sarcoma there was a marked deficiency of serum IgA and IgM, with minimal amounts of the M-components. In Case 150 (lymphosarcoma) the M-component (IgG) was recognized ultimately in the terminal stage of the disease, while in Case 155 (lymphatic leukemia) and in Case 156 (reticulum cell sarcoma) the M component (IgG or IgM, respectively) seemed to be present throughout the course of the disease.
As a rule, in patients with chronic infections or prolonged sensitizations In Bence-Jones-type myeloma normal immunoglobulin levels were inversely proportional to the number of plasma cells. This correlation was further clarified in the same patient (Case 127). The coefficients of correlation of the number of plasma cells to IgG, IgA, and IgM levels were -0.79, -0.69, and -0.75, respectively.
DISCUSSION

Serum immunoglobulin changes
The serum level of immunoglobulins depends on a balance between their production (synthesis) and removal (catabolism). In immunologically com petent persons, the environmental antigenic stimulation plus the metabolic factors in the host determines the level of each serum immunoglobulin. In immunologically incompetent persons, the capabilities of central lymphoid organs,11 such as the bursa of Fabricius of birds and its mammalian equivalent, gut-associated lymphoid tissue, will of course come to the front. According to Fahey and Robinson,12 the rate of immunoglobulin synthesis seems to be the primary factor determining the level of serum immunoglobu lins. Elevated immunoglobulin synthesis occurs following increased antigenic stimulation or development of tumors of immunoglobulin-producing cells. Impaired synthesis of immunoglobulins results in agammaglobulinemia or dysgammaglobulinemia.
With IgG, the fractional catabolic rate varies in direct proportion to the concentration of IgG in the serum. Marked serum increases of other immunoglobulin classes do not accelerate IgG catabolism.12 With IgA and IgM, the catabolic rate is independent of their serum concentra tion. Excessive catabolism or excessive loss of immunoglobulins causes a reduction in all or selected immunoglobulins. 13 We have observed that in plasma cell myeloma of any type and primary macroglobulinemia almost all patients have a reduction of the normal immunoglobulins.9,14-16 This is true also in heavy chain disease,17 alpha chain disease,18 and 7S-macroglobulinemia19 (Table 2 ). In these plasmacytic and lymphocytic malignancies the lowered serum immunoglobulin levels appear to be based upon the reduced synthesis.20,21 However, the mechanism by which these disorders (malignancies of immunoglobulin-producing cells) reduce normal immunoglobulin synthesis is poorly understood.
On the basis of our present data and on the review of literatures, it seems that the reduction of normal immunoglobulins is probably caused by the following mechanisms: (1) Crowding out of the normal immunoglobulin-producing cells by the tumor cells. Early in the course of the disease or in localized plasmacytoma (solitary, extramedullary), there is often no reduction of normal immunoglobu lins, but sooner or later it eventually develops. Furthermore, normal immunoglobulins increase towards normal levels, when the M-components are decreased during successful treatment.6
In Bence-Jones myeloma an inverse relationship was observed between the number of plasma cells and normal immunoglobulin levels (Fig. 9) . The reduction of normal immunoglobulins may be based partly upon crowding out of the normal immunoglobulin-produc ing cells by the neoplastic cells synthesizing Bence-Jones proteins.
(2) Decreased production of normal immunoglobulins due to unknown extracellular factors associated with neoplastic proliferation:
The decrease in normal immunoglobulins did not always parallel the concentration of M components indicating the numbers of neoplastic cells within the body (Figs. 4 and 6). Furthermore, it may occur in advance of extensive tumor cell infiltra tions (Case 26).
(3) Increased catabolism of normal immunoglobulins: In IgG myeloma a shortened maintenance of normal IgG has been observed.22 While the catabolic rate of IgA and IgM is independent of their serum concentration, the fractional rate of catabolism of IgG varies in direct proportion to the concentration of serum IgG.13 (4) Humoral suppression of normal immunoglobulin-producing cells related to a feedback mechanism in protein synthesis:23,24 High serum IgG levels in primary macroglobulinemia were, in rare instances, considered to be due to the failure of the feedback mechanism.25 (5) Caggiano et al.16 speculated that genes related to M-components might suppress the production of normal immunoglobulins without structural changes. Depression of normal immunoglobulin synthesis in myeloma may be analogous to the case of thalassemia in which the net production of hemoglobin poly peptide chains is reduced.
(6) Immunologic deficiency may precede the neoplasm. Konda and Takiguchi26 reported that M-components occurred in x-irradiated, thymecto mized and appendectomized rabbits. Furthermore, M-components are observed in patients with primary immunologic deficiency diseases, such as ataxia telangiectasia,27 Wiskott-Aldrich's syndrome,28 familial metabolic disorder of unknown etiology in the plasma cell system,29 primary acquired hypogam maglobulinemia,28 and immunologic amnesia.30 In addition, myeloma associated with thymoma has been reported.31 In these patients and animals the impaired immunologic defence against a mutant monoclone is expected. As a result, this monoclone might proliferate invasively.
(7) Influence of genetic factors involved in control of immunoglobulin synthesis: Genetic factors seem to be involved in the synthesis of im munoglobulins. It has been clearly demonstrated that relatives of patients with lupoid hepatitis have a higher incidence of hypergammaglobulinemia than the general population.32 Furthermore, families have been reported in which polyclonal hypergammaglobulinemia, monoclonal gammopathy, and hypogammaglobulinemia have a high incidence.33 Plasma cell tumors can be induced only in a specific strain (BALB/c) of mice by the peritoneal instillation of mineral oil.34 Also in man, familial occurrence of monoclonal gammopathies has been described.35-37 From all these considerations, it seems that there might be genetically-determined, profound immunologic disturbances in patients with myeloma or primary macroglobulinemia. Presumably these mechanisms would be simultaneously involved in the reduction of normal immunoglobulins in a complicated manner.
As a rule, in benign monoclonal gammopathy there was no reduction of normal immunoglobulins.6,38 Moreover, a high positive correlation was found between the amount of M-components plus normal immunoglobulins of the same class and normal immunoglobulin levels (Figs. 4 and 6). Reduction of normal immunoglobulins found in a few cases of this group would be explained by the basic diseases. Lowered IgM levels in patients with epithelial neoplasms and M-components of type IgG or type IgA were noteworthy.
However, the number of cases is too small to draw definite conclusions. These results indicate that the immunologic homeostasis in the immunoglobulin-producing system was not severely disturbed.
As stated earlier, an outstanding characteristic of the potentially malignant type was a marked reduction of normal immunoglobulins. It is conceivable that the above-mentioned mechanisms assumed in myeloma or in primary macroglobulinemia might be involved in the decrease in normal immunoglobu lins. Thus, the condition may not be wholly benign and should be regarded as being potentially malignant. In these patients a severe reduction of normal immunoglobulins would probably be detected several years before the malignant proliferations become large enough to produce detectable lesions or M -components. Moreover, it is noteworthy that some characteristic features common in myeloma are also recognized in this group.1
Patterns of normal immunoglobulins in patients with lymphomas and M -components are more complicated. Lowered normal immunoglobulin levels occasionally seen in these patients can be explained not only on the basis of the production of M-components, but also on the basis of an inherent tendency to hypogammaglobulinemia in these disorders.15 The prognostic aspects of M components have been discussed in the preceding paper.1
Elevated concentrations of M-components may be due primarily to their rapid synthesis.20 On the assumption that all the immunoglobulin-producing cells produce immunoglobulin at a fixed rate, the concentration of M-components reflects the total number of immunoglobulin-producing cells. The higher the concentration of M-components, the greater the number of cells. Con sequently, successful treatment usually leads to a reduction of M-components.
However, an unusual case of primary macroglobulinemia has been reported39 in which the M-component decreased significantly and lymphosarcoma developed later in the course of a previously typical primary macroglobulinemia. In this case, it seems that tumor cells forming lymphosarcoma were less mature, rapidly growing, and did not produce an immunoglobulin. Therefore, it is clear that reduction of M-components is not always a good prognostic sign.
As we have seen, it is extremely important in the differentiation between benign and malignant proliferations of immunoglobulin-producing cells to determine quantitatively the changes observed among M-components and normal immunoglobulins.
Classification of monoclonal gammopathies
Since M-components are found in a variety of diseases, it is important to classify monoclonal gammopathies. Besides an all-inclusive classification, 40 several workers41,42 have proposed various classifications based on the pathogenetic relationship between primary diseases and M-components. In view of our data including the recent results concerning the pathogenesis of monoclonal gammopathy, we propose the following classification (Table 3) .
Primary (obligatory)-malignant (I, 1-7): This group includes myeloma, extramedullary plasmacytoma, primary macroglobulinemia, 7S-macroglobuline mia,19 heavy chain disease,17 alpha chain disease,18 and potentially malignant type.6,9 In these diseases M-components are the products of the proliferating cells ('primary') and are constantly, with few exceptions, demonstrable ('obligatory').
The clinical features common to this group are those of malignancy of varying degrees: weight loss, anemia, leukopenia, and other symptoms and signs which are usually present during neoplastic proliferation. Furthermore, it is important that in this group a marked reduction of normal immunoglobulins is more characteristic than a concentration of M-components above 1.0 to 2.0 g/100ml (Figs. 3, 5, 7 and 8) .
Primary (obligatory)-benign; genetically-determined type (I, 8): Although we have not yet observed this type, many reports describing familial incidences of myeloma37 and primary macroglobulinemia36 as well as malignant lym phomas43 are rapidly accumulating in recent years. Likewise, a familial feature has also been observed in patients with benign monoclonal gammopathy.35,37 Such findings suggest a genetic factor in these conditions. The author has termed familial cases with no evidence of progression a genetically -determined type, as proposed by Michaux and Heremans.42 Also in this type, M-components are primarily produced under genetic influence. It is conceivable that this type would be related to various familial immune disorders, such as malignant lymphoma, autoimmune diseases, and immunologic deficiency diseases. However, there is little evidence that M-components per se are unequivocally autoantibodies responsible for these autoimmune diseases.
In our opinion, in most of autoimmune diseases the intensive stimula tion of the immune system with initial polyclonal hypergammaglobulinemia may lead to the ultimate exhaustion of immune tissues on one hand and to increased tendency to malignant or monoclonal transformation on the other band. It seems especially important to assume the possibility that the latter phenomenon may be based on the former.88 In fact, there have been many reports of lymphoid tumors developing during the course of autoimmune diseases.62, 63, 66, 69 Cancer (II, 5): The appearance of M-components in association with malignant neoplasms of epithelial cell origin is well recognized.42,44,70,71 Such an association is not infrequent.
The primary sites of the associated neoplasms have been in almost all parts of the body. Six patients from our series are in this group. Their neoplasms were in the stomach (Case 178), the larynx (Case 180), the uterus (Cases 179 and 183), and the prostate (Cases 181 and 182). In another patient (Case 17) the coexistence of gastric cancer and IgG myeloma was observed. It remains to be determined whether the association of M -components with epithelial neoplasms implies a causal relationship44, 70 Idiopathic; aging and miscellaneous diseases (III, 1-2): M-components in this category are of idiopathic nature; that is, no specific diseases related to the appearance of M-components are apparent.
A population survey90 revealed that 64 out of 6,995 persons above 25 years of age had M-components (0.9%) and 19 of the 747 persons above 70 years of age (2.5%). Hallen47 reported similar data: M-components were discovered in 18 out of 571 subjects above 70 years of age (3.2%). In our series there were six cases (3% of the total). Although there is a large body of evidence indicating that the aging process is accompanied by an increasing incidence of benign monoclonal gammopathy, the exact relationship between these two conditions remains obscure. Impaired immunity in the aged91.92 and genetic abnormalities may also be responsible for the appearance of M-components.
M-components were also observed in this study in patients with diabetes mellitus, essential hypertension, cerebral apoplexy, gastric ulcer and polyp and prostatic hypertrophy and in a healthy middle-aged man.
The significance of these M-components is completely unknown. Important underlying diseases involved in the appearance of M-components may be concealed.
Th e broad group of 'benign monoclonal gammopathy' proposed here consists of primary and secondary-benign groups (I, 8; II, 2-9) and an idiopathic group (III, 1-2). The following features appear to constitute a common denominator in benign monoclonal gammopathy:
(1) The monoclonal proliferations of plasma cells or related cells seem to be self-limited and not-aggressive.
(2) As a rule, in benign monoclonal gammopathy other than the primary benign group, M-components seem to be 'secondary' to the underlying ('primary') diseases and are usually associated with a polyclonal hypergam maglobulinemia.
(3) In some cases the M-component disappears as the patient recovers (Case 167).42.57 (4) As a rule, anemia or a decrease in albumin is absent or only very slight.( 5) Though overt myeloma sometimes develops rapidly from a rudimentary monoclonal gammopathy,93 the concentration of M-components is below 2g/100 ml and remains constant for years.
(6) Serum normal immunoglobulin levels are increased rather than decreased.42 (7) The number of plasma cells in the bone marrow is usually less than 10%. Cytological abnormalities are absent or few.
However, the monoclone, initially benign in these conditions, may ultimately be neoplastic. In fact, cases have been reported which progressed to overt myeloma94-96 or primary macroglobulinemia97 many years after the initial detection of M-components. Consequently, most benign monoclonal gammopathies must be followed up for a long time before a final diagnosis can be made. Particularly in the almost asymptomatic potentially malignant type careful observation for a long period of time is required.
Pathogenetic concept in monoclonal gammopathies
Prior to the establishment of the pathogenetic concept of monoclonal gam mopathies, the author would like to assume that lymphoreticular malignancies, immunologic deficiency diseases, and autoimmune diseases form a 'trinity' in a pathogenetic and etiological sense (Fig. 10) . The combined occurrence of lymphoreticular malignancies and immunologic deficiency diseases within the same family as well as in the same patient has been reported repeatedly.6,98-100 Likewise, such a combination has been described between lymphoreticular malignancies and autoimmune diseases62,63,66,69,100-103 and between immunologic deficiency diseases and autoimmune diseases.100,104-106 Of course, the simulta neous occurrence of these three conditions in the same patient has also been recognized. 107, 108 It is clear that disorders of the immune tissues may form a common background for these three groups of diseases. The phenomenon of 'lymphoid chimerism (runt disease)' can be introduced as a concept to integrate the f ollowing pathogeneses and etiologies common in the three.6,1 mechanisms may be responsible for the occurrence of 'lymphoid chimerism', namely, for the coexistence of abnormally oriented lymphoid cells and normal lymphoid cells.
(1) Somatic mutation of lymphoid cells. The mutant cells are usually destroyed by normal immunologic mechanisms. In patients with immunologic deficiency diseases, however, they would form a graft and proliferate invasively. The so-called 'forbidden clone' producing autoantibodies, proposed by Burnet, may be derived from such mutant cells. Neoplastic proliferations of the forbidden clones might explain the association of lymphomas and autoimmune diseases. Abrupt onset of high fever, rapid deterioration of the general condition, marked weight loss, hepatosplenomegaly, leukopenia, lymphopenia and death after only six weeks of illness were observed by Tornyos et al.112 in the later course of chronic lymphatic leukemia. Autopsy revealed complete replacement of lymphoid tissues by Hodgkin's granuloma. These findings bear a considera ble resemblance to 'runt disease' or 'graft-versus-host reaction'.110,113,114 Since the mutant clones could not be destroyed by the impotent immunologic apparatus of chronic lymphatic leukemia, they would constitute a graft and react immunologically against the host lymphoid tissues (autoimmune phenomenon). We have reported similar findings developing in the later course of reticulosis, which were suggestive of the graft-versus-host reaction seen in animals. 115, 116 (2) Maternofetal transplantation of lymphoid cells. Desai and Creger117 have demonstrated the transplancental passage of lymphocytes from mother to fetus. The possibility of human lymphoid chimerism based on the maternofetal transplacental passage has been suggested and the relation of this concept to lymphomas or autoimmune diseases has been discussed.117,118 However, there is no evidence for permanent colonization of such transplanted lymphoid cells and their immunologic function. Such transplanted cells seem to be rejected by normal fetuses, while they would probably form a graft in infants with immunologic deficiency disease,119 or under certain other circumstances.
Of importance in this regard are the animal models presented by Schwartz and Beldotti.120 About one third of the Fi hybrid mice which survived the graft versus-host reaction produced by transplantation of parental lymphoid cells developed lymphoma, in which the histopathology was similar to that of Hodgkin's disease in man.
(3) Blood transfusion and bone marrow transplantation. When competent lymphoid cells have been transferred into the patients in immunologic deficiency states by these procedures, severe bone marrow aplasia, lymphoid tissue depletion, and generalized histiocytosis with marked erythrophagocytosis have been observed.121 These findings are suggestive of graft-versus-host reaction. Waller et al.122 reported that some patients with renal transplants had evidence of autoimmune disease. This phenomenon might be due to the graft-versus-host reaction produced by renal transplants with foreign lymphoid tissues. Furthermore, the occurrence of reticulum cell sarcoma after repeated injections of gamma globulins123 and the development of reticulum cell sarcoma at the site of antilymphatic globulin injection124 could be understood as a result of the immunologic reaction of the injected immune globulins (graft) to the host.
(4) X-irradiation and immunosuppressive agents. These known oncogenic agents produce chromosomal aberrations on one hand and immunologic deficiency states on the other hand. Such chromosomal aberrations could lead to cell death and to accelerated proliferation of the surviving cells. These surviving cells would have increased susceptibility to somatic mutation and might form a graft on the basis of immunologic deficiency.125 Furthermore, immunologic deficiency states produced by these agents would facilitate the establishment of naturally occurring mutant clones, which are usually rejected by the normal immune apparatus.
(5) Viral infections. There are indications that the virus could have an effect on the immunologic competence of the lymphoid cells and trigger abnormal immune responses and immunologic diseases. In recent years, possible roles of viruses in the pathogenesis of immunologic diseases, such as lymphomas126-128 autoimmune diseases,129 and immunologic deficiency diseases130 have been noticed in man as well as in animal models. These clinical and experimental data could be explained on the assumption that a virus infection might produce 'foreign' -type lymphoid cells and the virus-transformed ('foreign') cells could react against the host cells in such a way as to lead either to autoimmune disease or to neoplasm. This view would help explain virus-induced forms of homo logous disease.
(6) Chronic infections and prolonged sensitization.
Repeated benign stimulation of immune tissues probably causes rapid multiplication of lymphoid cells with increased susceptibility to somatic mutation. On the other hand, the excessive proliferation of lymphoid cells might lead to the ultimate exhaustion of immune tissues (immunologic deficiency states).
Some of these mechanisms might be often cooperative simultaneously, not always one by one, in the pathogeneses or etiologies of such immunologic diseases in a complicated manner under genetic factors. All these conside rations suggest that lymphoreticular malignancies, immunologic deficiency diseases, and autoimmune diseases form a 'trinity' and must be considered as a whole rather than individually.
Further support for this concept ('trinity theory') can be sought in the association of such immunologic diseases with monoclonal gammopathy. The monoclone, neoplastic, reactive, or genetically-determined, can be understood as a graft; that is, the occurrence of the monoclone represents the establishment of 'lymphoid chimerism' (Fig. 11) . Consequently, the above-mentioned mechanisms responsible for 'lymphoid chimerism' may underlie the patho geneses or etiologies of monoclonal gammopathies. This concept affords a sound basis for the classification of monoclonal gammopathies presented here ( Grateful acknowledgment is made to many physicians who kindly gave specimens and clinical data to our laboratory.
Appendix
Case 7. A 75-year-old man was admitted with a four-month history of hemorrhagic tendency.
Blood studies showed severe anemia and thrombocytopenia . Although well circumscribed osteolytic lesions were present in the skull and 4th and 5th lumbar vertebrae , sternal marrow aspiration disclosed 3.8% relatively mature plasma cells . Besides the 
